6919.TW Stock — Price, Charts & Analysis

CALIWAY BIOPHARMACEUTICALS CO L (6919.TW) has no trailing P/E shown and a forward P/E of 20.30x. This places 6919.TW in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

6919.TW trades with 20.30x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether 6919.TW looks overvalued or undervalued.

6919.TW's P/E of 20.30x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

6919.TW's trailing EPS is -NT$0.16 and forward EPS is NT$5.37.

EPS, or earnings per share, shows how much profit CALIWAY BIOPHARMACEUTICALS CO L generated for each share. 6919.TW's trailing EPS is -NT$0.16, and investors usually prefer EPS that is positive and growing over time.

CALIWAY BIOPHARMACEUTICALS CO L has a market cap of NT$169.65B, making 6919.TW a large-cap stock based on the current market value shown on Worldtickers.

6919.TW's latest stock price on Worldtickers is NT$109.00. The latest move is NT$6.50 or 6.34%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

6919.TW's quote includes a latest price of NT$109.00. The market open is NT$106.50. Previous close is NT$102.50. The intraday range is NT$104.50 to NT$109.50.

6919.TW is up in the latest quote, with a move of NT$6.50 or 6.34%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

6919.TW generated NT$29.39M in trailing revenue. Revenue growth is -70.80%, which helps show whether demand is expanding or slowing.

6919.TW's revenue growth is -70.80%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, 6919.TW does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -NT$257.81M.

Gross margin is 70.30%. Margins show how efficiently CALIWAY BIOPHARMACEUTICALS CO L turns revenue into profit.

CALIWAY BIOPHARMACEUTICALS CO L carries NT$107.95M and holds NT$4.05B in cash.

6919.TW holds NT$4.05B on its balance sheet.

6919.TW's book value per share is NT$5.92.

Institutions hold 8.46% of 6919.TW shares. Insiders hold 33.26% of shares. Ownership mix helps investors understand how much of CALIWAY BIOPHARMACEUTICALS CO L is held by professional investors and company insiders.

6919.TW has 1.56B shares outstanding. Float shares are 1.15B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for 6919.TW, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for 6919.TW is NT$5.37. Revenue growth is -70.80%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

6919.TW's trailing EPS is -NT$0.16. Forward EPS is NT$5.37. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

6919.TW is in the Healthcare sector. Its earnings multiple is 20.30x. Its latest displayed growth metric is -70.80%. Compare these figures with sector peers before deciding whether CALIWAY BIOPHARMACEUTICALS CO L is stronger or weaker than average.

6919.TW trades at NT$109.00. The stock trades at 20.30x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of CALIWAY BIOPHARMACEUTICALS CO L's fundamentals.

6919.TW risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 1.12, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

6919.TW should be compared with companies in Biotechnology. Its earnings multiple is 20.30x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

CALIWAY BIOPHARMACEUTICALS CO L (6919.TW) operates in Healthcare, specifically Biotechnology. Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated i

6919.TW trades on Taiwan. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

6919.TW stock is priced in TWD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

CALIWAY BIOPHARMACEUTICALS CO L's official website listed on Worldtickers is www.caliway.com.tw. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

CALIWAY BIOPHARMACEUTICALS CO L is headquartered in New Taipei City, Taiwan. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

6919.TW is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

6919.TW has traded between NT$75.10 and NT$277.00 over the past 52 weeks. At NT$109.00, it is 60.65% below the high and 45.14% above the low. The 52-week range helps gauge long-term price momentum.

6919.TW is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is NT$103.93 and its 200-day moving average is NT$124.99.

6919.TW's RSI is 55.03. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

6919.TW's latest RSI reading is 55.03, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for 6919.TW is near NT$97.50. Key resistance is near NT$113.00. Breaks above resistance or below support can change the short-term technical setup.

6919.TW's nearest reported support level is NT$97.50. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

6919.TW's nearest reported resistance level is NT$113.00. A breakout above resistance can improve momentum, especially when volume confirms the move.

6919.TW trades about 6.45M shares daily on average. The latest displayed volume is 6.01M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

6919.TW's MACD is -0.23, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

6919.TW is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 55.03 (neutral). MACD is bearish. Nearest support is around NT$97.50. Resistance is around NT$113.00. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is NT$105.29 (3.52% from price). MA50 is NT$103.93 (4.88% from price). MA200 is NT$124.99 (-12.80% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. 6919.TW's MA20 is NT$105.29. MA50 is NT$103.93. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

6919.TW's pivot is near NT$103.50. Support is near NT$97.50. Resistance is near NT$113.00. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for 6919.TW is near NT$101.43. The next upper resistance zone is near NT$115.20. These levels help define risk and possible follow-through zones after a breakout or breakdown.

6919.TW's Bollinger range is roughly NT$98.48 to NT$112.10. Band width is near 12.94%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

6919.TW's ATR-based typical daily range is about 5.05%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 6.01M shares. Average volume is about 6.45M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

6919.TW's all-time high shown on Worldtickers is NT$277.00. Its all-time low is NT$11.08. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

6919.TW has a beta of 1.12, meaning it has historically been more volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.